Table 1.
Scoring of tissue inflammation following oral and intraperitoneal delivery of curcumin nanoparticles prior to inoculation with CpG-ODN.
| Pre-Treatment | Dose d | CpG-ODN | Mouse | Pathology Score | Average Score per Mouse (±S.D.) |
|---|---|---|---|---|---|
| Water (Oral) | 0 | N | 1 | 0 | 0.33 (0.58) **,^ |
| 2 | 1 | ||||
| 3 | 0 | ||||
| Water (Oral) | 0 | Y | 1 | 2 | 1.67 (0.58) * |
| 2 | 1 | ||||
| 3 | 2 | ||||
| Vehicle-Only Nanoparticles (Oral) | 0 | Y | 1 | 1 | 1.17 (0.52) * |
| 2 | 2 | ||||
| 3 | 2 | ||||
| 4 | 1 | ||||
| 5 | 1 | ||||
| 6 | 0 | ||||
| Vehicle-Only Nanoparticles (IP) | 0 | Y | 1 | 1 | 1.20 (0.84) * |
| 2 | 2 | ||||
| 3 | 1 | ||||
| 4 | 2 | ||||
| 5 | 0 | ||||
| Curcumin Nanoparticles (Oral) | 1.25 | Y | 1 | 1 | 1.67 (0.52) * |
| 2 | 1 | ||||
| 3 | 2 | ||||
| 4 | 2 | ||||
| 5 | 2 | ||||
| 6 | 2 | ||||
| Curcumin Nanoparticles (IP) | 1.25 | Y | 1 | 0 | 0.80 (1.1) * |
| 2 | 2 | ||||
| 3 | 0 | ||||
| 4 | 2 | ||||
| 5 | 0 | ||||
| Curcumin Nanoparticles (IP) | 2.4 | Y | 1 | 2 | 1.16 (0.75) * |
| 2 | 1 | ||||
| 3 | 2 | ||||
| 4 | 1 | ||||
| 5 | 1 | ||||
| 6 | 0 | ||||
| Curcumin Nanoparticles (IP) | 4.8 | Y | 1 | 0.5 | 1.50 (0.87) * |
| 2 | 2 | ||||
| 3 | 2 |
d—dose (mg) of curcumin in nanoparticles. Statistical significance (Kruskal–Wallis test of one-way ANOVA with Dunn’s multiple comparisons test) and with alpha < 0.05 compared to: negative control *; CpG only positive control **; vehicle-only nanoparticles ^. IP = intraperitoneal.